Company Overview
Biofourmis is a digital therapeutics and AI-powered remote patient monitoring company focused on high-acuity patients — particularly those with heart failure, oncology diagnoses, and post-surgical recovery needs. The company uses FDA-cleared wearable sensors combined with AI analytics to continuously monitor biometric data and predict clinical deterioration before it becomes a hospitalization event.
Biofourmis has raised approximately $320 million and developed the BiovitalsHF platform — an AI model predicting heart failure deterioration days in advance. The company also operates hospital-at-home programs with major health systems and works with pharmaceutical companies to generate real-world evidence from participants monitored continuously at home.
Products & Platform
Market Position
Biofourmis occupies the high-acuity end of the remote monitoring spectrum — serving the most complex patients with the most sophisticated AI analytics. Its FDA-cleared deterioration prediction and pharmaceutical partnerships differentiate it from general-purpose platforms. As MA plans and ACOs take greater financial responsibility for post-acute outcomes, predicting deterioration in high-risk patients becomes a financial and quality differentiator.
Key Data & Metrics
| Metric | Detail |
|---|---|
| Total Funding | ~$320M raised |
| Founded | 2016 |
| Headquarters | Boston, MA |
| FDA Status | FDA-cleared deterioration prediction algorithms |
Recent News & Developments
How Dorthea Uses This Technology Category
Dorthea's AI co-pilot helps families understand how platforms like Biofourmis affect the quality and accountability of senior care facilities and home care agencies they are evaluating. Our free guidance helps families ask the right questions.